SynthesisEuropean journal of clinical pharmacology2026
Response to alemtuzumab-based therapy and long-term survival after allogeneic transplantation in T-Cell prolymphocytic leukemia: a systematic review and meta-analysis of proportions.
Synthesis in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionT-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive neoplasm with poor outcomes. Alemtuzumab and allogeneic hematopoietic cell transplantation (allo-HCT) are the mainstays of treatment, yet estimates rest on small single-arm studies, and no synthesis has pooled both outcomes. We quantified response to alemtuzumab-based therapy and long-term survival after allo-HCT.
methodsWe performed a systematic review and meta-analysis of proportions. MEDLINE, CENTRAL, ClinicalTrials.gov, Google Scholar, were searched from inception to June 2026. Studies reporting response to alemtuzumab-based therapy or survival after allo-HCT in adults with T-PLL were eligible. Sensitivity analyses assessed robustness, while publication bias (Egger's test), risk of bias (JBI), and certainty (GRADE) were assessed.
resultsSeven studies (200 patients) informed the primary analysis. The pooled overall response rate was 81.9% (95% CI 66.6-91.1; I²=78%) and complete response rate 58.5% (95% CI 39.6-75.2; I²=76%); heterogeneity was explained by line of therapy (frontline 85%, relapsed/refractory 51%; p<0.0001). Across three independent registries (363 patients), long-term survival after allo-HCT was 30.3% (95% CI 25.8-35.3; I²=0%).
conclusionsAlemtuzumab-based therapy was associated with high response rates in T-PLL-approximately 85% frontline-and approximately one-third of transplanted patients achieved long-term survival. These pooled values are descriptive benchmarks derived from low-certainty, single-arm evidence and require prospective confirmation.
Indexed as
Identifiers
42720768What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.